Pro-adrenomedullin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival

Huadong Yan\textsuperscript{a,b,c}, Susu Jin\textsuperscript{c}, Lili Liang\textsuperscript{c}, Jingyuan Du\textsuperscript{c}, Guruprasad P. Aithal\textsuperscript{d,e} and Lanjuan Li\textsuperscript{a}

\textsuperscript{a}State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Centre for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China; \textsuperscript{b}Department of Hepatology, Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital, Ningbo No.2 Hospital, University of Chinese Academy of Sciences, Ningbo, China; \textsuperscript{c}Department of Hepatology, Hwamei Hospital, Ningbo No.2 Hospital, Ningbo University School of Medicine, Ningbo, China; \textsuperscript{d}NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK; \textsuperscript{e}Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK

ABSTRACT

Background and aim: Acute-on-chronic liver failure (ACLF) is characterized by the presence of acute decompensation (AD) of cirrhosis, organ failures, and high short-term mortality rates. In present study, we explored whether Pro-adrenomedullin (Pro-ADM), a biomarker of sepsis, is a potential marker of outcome in patients admitted for AD or ACLF and whether it might be of additional value to conventional prognostic scoring systems in these patients.

Methods: 332 consecutive patients with AD of cirrhosis were prospectively enrolled. Pro-ADM was measured for all patients at baseline. Cox regression analysis was used to evaluate the impact of pro-ADM on short-term survival and developing ACLF during hospital stay.

Results: Serum pro-ADM levels were significantly high in non-survivors ($p < .001$) and showed significant correlation with ALT ($r = 0.181$, $p = .001$), INR ($r = 0.144$, $p = .009$), TB ($r = 0.368$, $p < .001$), Creatinine ($r = 0.145$, $p = .004$), MELD score ($r = 0.334$, $p < .001$) and CLIF-C OF score ($r = 0.375$, $p < .001$). Serum pro-ADM at admission was shown to be a predictor of 28-day mortality independently of MELD and CLIF-C OF scores. Prognostic models incorporating pro-ADM achieved high C index for predicting 28-day mortality in AD patients of cirrhosis. Moreover, baseline pro-ADM was found to be predictive of ACLF development during hospital stay.

Conclusions: Serum pro-ADM levels correlate with multiorgan failure and are independently associated with short-term survival and ACLF development in patients admitted for AD or ACLF.

Introduction

Acute decompensation (AD) of liver cirrhosis is characterized by the development of major complications of the underlying liver disease and currently represents one of the most common causes of admission to hospital in patients with cirrhosis [1,2]. Acute-on-chronic liver failure (ACLF) is a complex syndrome that occurs in patients with AD, and is characterized by organ failures and high short-term mortality [2–4].

Adrenomedullin (ADM), a peptide with 52 amino acids, is released from multiple tissues in response to physiological stress or after infection [5,6]. It has vasodilatory anti-inflammatory and antimicrobial properties, and can be enhanced by the regulation of the complement system [5]. It is found elevated in several critical diseases, including cardiovascular and renal disorders, sepsis, cirrhosis, cancer, and diabetes [6–8]. However, ADM is quickly cleared from circulation, making the measurement unreliable [9]. The midregional fragment of pro-adrenomedullin (pro-ADM), comprising amino acids 45–92, is more stable than the active ADM peptide and it has been detected in plasma of patients [10]. Recently, pro-ADM has been found useful as a marker of organ damage and predictor of mortality in patients with sepsis [11]. It has also been associated with increased mortality in patients with chronic heart failure (CHF) and can be used as a powerful new prognostic marker of death or heart failure in patients with acute myocardial infarction (AMI) [12,13]. However, the prognostic value of pro-ADM and its correlation with organ failure and ACLF in patients with AD of cirrhosis have not been evaluated so far.

In the present study, we aimed to evaluate pro-ADM as a potential marker of outcome in patients admitted for AD or ACLF and whether it might be of additional value to conventional prognostic scoring systems in these patients.
Patients and methods

Study design

Patients were prospectively screened and enrolled from January 2016 to June 2017 in hepatology department, Hwamei Hospital, Ningbo No.2 Hospital, University of Chinese Academy of Sciences. All acute decompensated cirrhosis patients were assessed and diagnosed by liver biopsy, a composite of clinical signs and findings provided by laboratory tests, endoscopic signs of portal hypertension, radiological evidence of liver nodularity or clinical evidence of prior hepatic decompensation. The study fulfilled the principles of the Declaration of Helsinki and was approved by the ethics committee of Ningbo No.2 Hospital. Written informed consent was obtained from each participant or their legal representatives before enrollment. All authors had access to the study data and had reviewed and approved the final manuscript.

Patients

Patients with a new episode of acute decompensation (AD) were prospectively screened and enrolled. Events of acute decompensation included overt ascites, upper gastrointestinal bleeding, hepatic encephalopathy and bacterial infection. Causes of exclusion are summarized in Figure 1. Patients were excluded based on the following criteria as previously described [14]: (i) age < 18 years; (ii) pregnancy; (iii) hepatocellular carcinoma (HCC) outside Milan criteria or other types of tumors; (iv) chronic renal diseases [estimated-glomerular filtration rate (eGFR) < 90ml/min] and other severe co-morbidities such as myocardial infarction, subarachnoid or cerebral hemorrhage; (v) HIV infection.

Data collection

We collected the following clinical and demographic information in a pre-specified datasheet: age, sex, etiologies of cirrhosis, admission events, medical history for previous hospitalization, anti-viral treatment, and other treatment, laboratory parameters, events of organ failures, and prognosis.

ACLF was defined by the EASL-ACLF criteria, CLIF-C OF score was used to define six organ failures including liver, coagulation, kidney, circulation, lung and brain failure [2,15]. Bacterial or fungal infections were diagnosed as previously described: (i) pneumonia: new pulmonary infiltrate with fever, respiratory symptoms, findings on auscultation, or WBC count > 10,000/mm³ or < 4000/mm³; (ii) spontaneous bacterial peritonitis (SBP): poly-morphonuclear cells in ascitic fluid > 250/mL; (iii) bacteremia: positive blood cultures without a source of infection; (iv) urinary tract infection: urine WBC > 10/high power field with positive culture and symptom of urinary irritation; (v) others bacterial infections included skin infection and intra-abdominal infection; (vi) fungal infection: positive fungal culture.

The management of enrolled patients was first focusing on acute precipitating events and complications to support organ dysfunction and failure. Patients with bacterial infection were immediately treated with empirical antibiotic therapy and then based on bacteria culture and antibiotics sensitivity test. In addition, weight-based intravenous albumin was used in patients with SBP and AKI. Diagnostic abdominocentesis were performed in patients with ascites to examine the whether SBP was present. Those with moderate ascites were treated with restriction of sodium intake and/or diuretics (aldosterone antagonist and/or furosemide). Paracentesis combining with intravenous albumin was used in those with large or refractory ascites. All patients with acute variceal bleeding received intravenous somatostatin, proton pump inhibitors (PPI) and antibiotic prophylaxis. For those with uncontrolled hemorrhage due to pharmacological therapy, Sengstaken-Blackmore tube and/or urgent therapeutic endoscopy were performed. Patients with renal failure were treated with intravenous albumin, vasoconstrictors (such as dopamine, noradrenaline or terlipressine) or renal replacement therapy, and potential precipitating events were investigated. Patients with hepatic encephalopathy were given lactulose, antibiotics and L-ornithine aspartate, and potential precipitating events were investigated; Fluid replacement was performed in patients with MAP < 70 mmHg, and vasoactive agents were used when necessary. Oxygen therapy was performed in patients with decreased PaO2 or SpO2; nasal catheter, mask or venture mask oxygen inhalation or mechanical ventilation were chosen according to the severity of respiratory dysfunction. Lastly, intravenous high glucose, albumin or plasma were used as clinically indicated, glutathione, adenosylmethionine or branched-chain amino acids were used as nutritional support. The follow-up of patients started at onset of hospital admission. For patients discharged from hospital, prognostic information was obtained from medical records, telephone contact or visiting. The primary endpoint of the study was 28-day, 90-day transplant-free mortality.

Pro-ADM measurements

Blood samples were collected under standardized conditions in plasma collection tubes containing ethylenediaminetetraacetic
see that the pro-ADM level was determined by quantitative sandwich enzyme immunoassay technique as extensively described [16], according to the manufacturer’s recommendations (all kits from Cusabio Biotech Co., Ltd., Wuhan, China).

**Statistical analysis**

Continuous variables were expressed as the mean ± standard deviation (SD) or the median with the interquartile range. Binary or nominal variables were expressed as a number and percentage of the total patient population. Groups were compared using Student’s t-test, the Mann–Whitney U-test, or a Chi-squared test. Linear regression analysis was used to compare the correlation between groups. Survival curves were drawn to describe subgroups of patients; the cumulative incidence of death was compared using the Log–rank test. Cox regression analysis was performed to identify factors associated with multiple outcomes. For all multivariate analyses, univariate analysis was performed to screen the potential risk factors of poor prognosis. Then, candidate variables (p-value < .10) were entered into multivariate analysis. The discrimination of several prognostic models was measured by C-index. Changes of pro-ADM prior mortality were visualized via locally weighted scatterplot smoothing (LOESS) plot. Confidence intervals were given for the 95% level. Differences were considered significant if the p-value was less than .05. Statistical analyses were performed using SPSS 16.0 (SPSS Inc, Chicago, IL, USA) or GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).

**Results**

**Patients**

As shown in Figure 1, 469 patients with cirrhosis of the liver were candidates for enrollment, out of which 332 patients with AD were included in the study and 133 patients were excluded as they fulfilled either one or more of exclusion criteria. Another 30 compensated cirrhosis patients and 30 healthy people were included as control groups. The baseline characteristics of the study cohort were shown in Table 1. There were 231 (69.6%) males and mean age of the patients was 57 ± 13. The etiology of cirrhosis was related to hepatitis B in 194 (58.4%), alcohol in 46 (13.9%), hepatitis B plus alcohol in 32 (9.6%), others in 42 (12.7%) and cryptogenic in 18 (5.4%). 98 (29.5%) patients experienced previous decompensation. Ascites was seen in 233 (70.2%) patients and 32 (9.6%) patients had HE. Bacterial was present in 60 (18.1%) patients and 54 (16.3%) patients had GI bleeding. The median pro-ADM concentration was 11.8 (12.9) nmol/L. 36 (10.8%) patients had ACLF at admission. Characteristics of patients with or without ACLF were shown in Supplement Table 1.

**Correlation between serum pro-ADM with diseases severity**

As shown in Figure 2, the pro-ADM in AD patients was significantly high than those in healthy control group and the compensated cirrhosis group (both p < .001). Furthermore, the pro-ADM in ACLF patients was significant high than those in AD without bacterial infection (p < .001). The difference of pro-ADM between ACLF patients and AD with bacterial infection was not statistically significant (p = .056).

Baseline characteristics of patients based on their pro-ADM concentration (pro-ADM ≤ 11.8 nmol/L vs pro-ADM >11.8 nmol/L) were shown in Supplement Table 2. The high pro-ADM patients had significantly high levels of ALT, AST, TB, INR, WBC, and CRP as well as disease severity scores such as CTP score, MELD score and CLIF-C OF score. The high pro-ADM patients had significantly high 28-day mortality and 90-day mortality.

As shown in Figure 3, pro-ADM correlated with ALT (r = 0.181, p = .001), INR (r = 0.144, p = .009), TB (r = 0.368, p < .001), Creatinine (r = 0.145, p = .004), MELD score (r = 0.334, p = <.001) and CLIF-C OF score (r = 0.375, p = <.001). Pro-ADM was correlated with bacterial infection in cirrhotic patients (r = 0.108, p = .048). As shown in Supplement Table 3, pro-ADM was a predictors of bacterial infection on univariate logistic regression analysis (p = .050). But on multivariate logistic regression analysis, WBC count and CRP were independent predictors of bacterial infection. The performances of CRP and WBC count for predicting bacterial infection were 0.696 (AUROC; 95% CI: 0.643–0.745) and 0.674 (AUROC; 95% CI: 0.621–0.724), significantly higher than pro-ADM (AUROC, 0.576, 95% CI: 0.521–0.630), (p = <.001).

The WBC and CRP value in ACLF patients and AD with bacterial infection were all significantly higher than those in AD without bacterial infection (both p < .001). But the WBC and CRP value in ACLF patients were significant high than those in AD without bacterial infection (p < .001). WBC and CRP value between ACLF patients and AD with bacterial was not significant (p = .34 and .51, respectively).

**Evaluate the impact of pro-ADM on short-term survival**

At 28 days after enrolment in the study, 19 (5.7%) patients died and 2 (0.6%) received a liver transplantation. After 90 days of follow-up, 37 (11.1%) patients died and 8 (2.4%) were transplanted. The main causes of death at 28 and 90 days were listed in Supplement Table 5. Serum pro-ADM was found to be significantly higher in patients who died or were transplanted as compared to those who were still alive without liver transplantation at 28 days follow-up (21.1 ± 1.3 vs. 1.1(1.2) nmol/L, p < .001). Figure 4 shows the estimated probability of death after 28 and 90 days of follow-up according to serum pro-ADM concentration, showing that high serum pro-ADM concentrations have an additional negative impact on mortality risk.

The univariate cox regression analysis of various predictors with 28 day survival are also listed in Table 2. The predictors which were significant on univariate analysis were
Table 1. Baseline characteristics of the study cohort.

| Characteristic                  | AD patients (N = 332) | Compensated cirrhosis (N = 30) | Healthy control (N = 30) | p value |
|--------------------------------|-----------------------|---------------------------------|--------------------------|---------|
| Age (years)                    | 56.6 ± 12.8           | 52.8 ± 11.4                     | 34.4 ± 8.3               | <.001   |
| Male No. (%)                   | 231 (69.6)            | 23 (76.7)                       | 13 (43.3)                | .007    |
| DM No. (%)                     | 53 (16.0)             | 3 (10.0)                        | –                        | .39     |
|MAP (mmHg)                      | 89.8 ± 12.4           | –                               | –                        | N       |
|Previous decompensation No. (%)| 98 (29.5)             | –                               | –                        | .60     |
| **Etiology**                   |                       |                                 |                          |         |
| HBV No. (%)                    | 194 (58.4)            | 16 (53.3)                       | –                        |         |
| Alcohol No. (%)                | 46 (13.9)             | 4 (13.3)                        | –                        |         |
| HBV plus alcohol No. (%)       | 32 (9.6)              | 4 (13.3)                        | –                        |         |
| Others* No. (%)                | 42 (12.7)             | 3 (10.0)                        | –                        |         |
| Cryptogenic No. (%)            | 18 (5.4)              | 3 (10.0)                        | –                        |         |
| **Admission events**           |                       |                                 |                          |         |
| Ascites No. (%)                | 233 (70.2)            | –                               | –                        | N       |
| GI bleeding No. (%)            | 54 (16.3)             | –                               | –                        | N       |
| Bacterial infection No. (%)    | 60 (18.1)             | –                               | –                        | N       |
| HE No. (%)                     | 32 (9.6)              | –                               | –                        | N       |
| **Laboratory data**            |                       |                                 |                          |         |
| ALT (IU/L)                     | 42.5 (88.8)           | 31.5 (23.5)                     | 16.0 (13.5)              | <.001   |
| AST (IU/L)                     | 61.0 (108)            | 31.0 (26.3)                     | 18.5 (8.5)               | <.001   |
| Albumin (g/dL)                 | 29.1 ± 5.5            | 38.2 ± 5.3                      | 46.8 ± 2.8               | <.001   |
|TB (µmol/l)                     | 38.5 (126)            | 13.6 (8.7)                      | 15.4 (6.7)               | <.001   |
| Hemoglobin (g/L)               | 110 ± 24.4            | 137 ± 17.3                      | 143 ± 16.2               | <.001   |
|International normalized ratio  | 1.5 (0.6)             | 1.2 (0.2)                       | –                        | <.001   |
|Serum sodium (mmol/L)           | 138 ± 4.9             | 141 ± 3.0                       | 140 ± 2.0                | .001    |
|WBC count (10⁹/L)               | 5.0 (4.2)             | 4.4 (2.7)                       | 5.9 (1.5)                | .06     |
|Creatinine (µmol/L)             | 64.2 (26.0)           | 59.1 (16.4)                     | 52.2 (27.5)              | .006    |
|Platelet count (10⁹/L)          | 77.5 (66.0)           | 98.0 (90.3)                     | 221 (56.8)               | <.001   |
|CRP (mg/L)                      | 8.8 (14.0)            | –                               | –                        | N       |
|Pro-ADM (nmol/L)                | 11.8 (12.9)           | 5.0 (5.4)                       | 3.2 (1.5)                | <.001   |
| **Disease Severity**           |                       |                                 |                          |         |
|CTP class                       |                       |                                 |                          | <.001   |
|A No. (%)                       | 0 (0)                 | 30 (100.0)                      | –                        |         |
|B No. (%)                       | 58 (17.5)             | 0 (0)                            | –                        |         |
|C No. (%)                       | 274 (82.5)            | 0 (0)                            | –                        |         |
|CTP score                       | 11.0 (2.0)            | 5 (1)                            | –                        | <.001   |
|MELD score                      | 10.6 (12.2)           | 3.0 (7.3)                       | –                        | <.001   |
|CLIF-C OF score                 | 6.0 (2.0)             | 5 (0)                            | –                        | <.001   |
|ACLF No. (%)                    | 36 (10.8)             | –                               | –                        | N       |

Data are expressed as mean ± standard deviation (SD), median (interquartile range) or number (percent). AD: acute decompensation; HBV: hepatitis B virus; GI bleeding: gastrointestinal bleeding; HE: hepatic encephalopathy; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TB: total bilirubin; INR: International normalized ratio; WBC: white blood cell; CRP: C-reactive protein; CTP: Child-Turcotte-Pugh; MELD: Model for End-Stage Liver Disease; CLIF-C OF: The Chronic Liver Failure-consortium organ failure; *Other etiologies of cirrhosis included HCV, autoimmune liver diseases, schistosomiasis, Wilson disease, non-alcoholic steatohepatitis (NASH) and hemachromatosis. Statistical analysis among groups was performed using Student’s t-test, the Mann–Whitney U-test, or a Chi-squared test.

pro-ADM (p < .001), bacterial infection (p = .018), hepatic encephalopathy (p < .001), AST (p = .003), albumin (p < .001), total bilirubin (p < .001), INR (p < .001), Serum sodium (p = .005), WBC count (p < .001), creatinine (p < .001), CRP (p = .004), CTP score (p < .001), MELD score (p < .001), MELD-Na score (p < .001), CLIF-C OF score (p < .001).

Of all the significant predictors on univariate analysis, further multivariate cox regression analysis based on CLIF-C OF score or MELD score was done. Two different prognostic models were developed each incorporating pro-ADM (as selection variable) (Table 3) along with different combinations of WBC count, CLIF-C OF score, MELD score. Moreover, prognostic models incorporating pro-ADM achieved high C index for predicting 28-day mortality in AD patients of cirrhosis (MELD + pro-ADM + WBC vs MELD, 0.846 vs 0.753, p = .026; MELD + pro-ADM vs MELD, 0.797 vs 0.753, p = .096; CLIF-C OF + pro-ADM + WBC vs CLIF-C OF, 0.871 vs 0.787, p = .020; CLIF-C OF + pro-ADM vs CLIF-C OF, 0.837 vs 0.787, p = .046; Table 4).

Kaplan–Meier curves showed highest mortality for patients with high pro-ADM (>11.8 nmol/mL) and presence of ACLF (Figure 5(A,B)). Similarly patients with high pro-ADM (>11.8 nmol/mL) and high MELD score (>12.2) had the worst survival (Figure 5(C,D)).

Finally, as shown in Supplement Table 4, a Univariate cox regression analysis and multivariate cox regression analysis was performed in order to identify the independent predictive factors for ACLF development during hospital stay (n = 34). Serum pro-ADM, together with WBC and MELD score was found to be an independent predictive factor for ACLF development.

**Discussion**

AD of liver cirrhosis continues to be a major cause of mortality and is directly related to the severity of organ damage in many cirrhotic patients [2,3]. In present study, we assessed the prognostic ability of pro-ADM in patients admitted with AD or ACLF. The results demonstrate that pro-ADM is significantly correlated with organ failure and short-term mortality and can be used as a biomarker for prognosis in patients with AD or ACLF.
Previous reports had underlined that pro-ADM shows good predictive power in several critical diseases, including sepsis, CHF and AMI [11–13]. A study with 213 consecutive hospitalized patients with cirrhosis and ascites showed that pro-ADM may be a promising marker to identify patients with bacterial infections as well as patients at risk of short-term mortality [17]. However, little is known about the prognostic value of pro-ADM in patients with AD and ACLF. In present study, we assessed pro-ADM as a potential marker of early mortality in a cohort of 332 AD patients of cirrhosis. Compared with healthy control group and stable cirrhotic patients, pro-ADM concentration was significantly high in patients with AD and even higher in ACLF patients. Pro-ADM had a significant positive correlation of pro-ADM with several liver damage indexes, including ALT, TB and INR. We also found a significant difference in MELD and CLIF-SOFA scores which are already established prognostic scores in patients with decompensated cirrhosis between the two groups. However, there was no significant difference in bacterial infection between the two groups. Pro-ADM was less specific in predicting bacterial infection or sepsis than CRP and WBC count in patients with decompensated cirrhosis in our cohort. Furthermore, we found serum pro-ADM predicted mortality independently after adjusting for all these predictors on multivariate analysis. Prognostic models incorporating pro-ADM achieved high C index for predicting 28-day mortality in patients with decompensated cirrhosis (Table 4). Kaplan–Meier curves showed an increased mortality with high pro-ADM concentration and presence of ACLF or high MELD scores (Figure 5). In addition, pro-ADM was also an independent risk factor for the development of ACLF.

Pro-ADM release in patients with decompensated cirrhosis is most likely related to three possible mechanisms. First, ADM gene expression can be up-regulated by a variety of factors, including endotoxin and cytokines [18,19]. Plasma levels of endotoxin and endotoxin-related cytokines are

![Figure 2. Comparison of serum pro-ADM in subgroups: (A) Comparison of pro-ADM in healthy control, compensated cirrhosis and AD patients; (B) (C) and (D), compare pro-ADM, WBC and CRP across groups of ACLF and AD with or without bacterial infection. ACLF: acute-on-chronic liver failure; AD: acute decompensation; WBC: white blood cell; CRP: C-reactive protein.](image-url)
Figure 3. Correlation between serum pro-ADM with ALT, INR, TB, Creatinine, MELD and CLIF-C OF and ALT: alanine aminotransferase; TB: total Bilirubin; INR: International normalized ratio; WBC: white blood cell; MELD: Model for End-Stage Liver Disease; CLIF-C OF: The Chronic Liver Failure-consortium organ failure.

Figure 4. Changes of pro-ADM prior 28-day (A) and 90-day (B) mortality were visualized via locally weighted scatterplot smoothing (LOESS) plot. Shaded region depicts 95% confidence interval.
ADM concentration in patients with cirrhosis may be a result of decreased renal clearance. Previous reports have found that ADM concentration is elevated in patients with renal failure [23]. However, there are still numerous unknown mechanisms of ADM system in patients with decompensated cirrhosis and needing to be further explored.

There are several limitations to our study. This was a single-center study, and the results need to be replicated in larger multicenter studies. Number of patients with sepsis in our cohort is small. As a result, the association between pro-ADM and patients with sepsis might need further study to confirm. In addition, as the study was focused on examining the value of pro-ADM at the baseline on the short-term outcome of cirrhosis with acute decompensation, we are unable to investigate the effect of interventions during the hospital stay on pro-ADM levels. We have also presented the mean values of this biomarker in healthy controls and group of compensated cirrhosis. These latter groups aren’t age and sex matched to the study group.

In summary, our findings demonstrated that serum pro-ADM levels correlate with multiorgan failure in patients with decompensated cirrhosis. In addition, pro-ADM is a predictor of short-term mortality in cirrhotic patients admitted for AD, independently of MELD and CLIF-C OF scores. Serum pro-ADM shows the potential to add relevant prognostic value to these prognostic scoring systems. Altogether, these findings suggest that pro-ADM is an interesting potential prognostic marker in hospitalized cirrhotic patients with AD and ACLF.
Acknowledgements

We would like to acknowledge the medical and nursing staff of the Liver center, Hwamei Hospital, Ningbo, for their work and help during the period of the study.

Disclosure statement

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest related to this manuscript.

Funding

This work was supported by the grants from Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2015KYB344), the Social Development Major Projects of Ningbo City (2016CS1005), Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2018ZD039), Zhejiang Provincial natural science foundation (LGF20H030006).

ORCID

Guruprasad P. Aithal http://orcid.org/0000-0003-3924-4830

References

[1] Ginès P, Schrier R. Renal failure in cirrhosis. N Engl J Med. 2009; 361(13):1279–1290.
[2] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–1437.
Bajaj JS, O’Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60:250–256.

Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2009;3(1):269–282.

Hirata Y, Mitaka C, Sato K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab. 1996;81(4):1449–1453.

López J, Martínez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol. 2002;221:1–92.

Guevara M, Ginés P, Jiménez W, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology. 1998;114(2):336–343.

Kojima H, Tsujimoto T, Uemura M, et al. Significance of increased plasma adrenomedullin concentration in patients with cirrhosis. J Hepatol. 1998;28(5):840–846.

Hinson J, Kapas S, Smith D. Adrenomedullin, a multifunctional regulatory peptide[J]. Endocr Rev. 2000;21(2):138–167.

Struck J, Tao C, Morgenthaler N, et al. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25(8):1369–1372.

Bernal-Morell E, García-Villalba E, Vera M, et al. Usefulness of mid-regional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J Infect. 2018;76(3):249–257.

Von Haelming S, Filippatos G, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Failure. 2010;12(5):484–491.

Khan S, O’Brien R, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2007;49(14):1525–1532.

Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology. 2015;62(1):232–242.

Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute on chronic liver failure. J Hepatol. 2014;61(5):1038–1047.

Morgenthaler N, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51(10):1823–1829.

Reukens PA, Kiehntopf M, Stallmach A, et al. Mid-regional pro-adrenomedullin (MR- proADM): an even better prognostic biomarker than C-reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection? J. Hepatol. 2012;57(5):1156–1158.

Linscheid P, Seboek D, Zulewski H, et al. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology. 2005;146(6):2699–2708.

Eto T, Kato J, Kitamura K. Regulation of production and secretion of adrenomedullin in the cardiovascular system. Regul Pept. 2003;112(1–3):61–69.

Devière J, Content J, Denys C, et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology (Baltimore, Md.). 1990; 11(4):628–634.

Fukui H, Brauner B, Bode J, et al. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol. 1991;12(2):162–169.

Liu H, Lee S. Acute-on-chronic liver failure: the heart and systemic hemodynamics. Curr Opin Crit Care. 2011;17(2):190–194.

Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest. 1994;94(5):2158–2161.